ABCL250117P5000
- 1.93
- 0.000.00%
AbCellera Biologics Newsroom
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $4
KeyBanc Cuts Price Target on AbCellera Biologics to $4 From $5, Keeps Overweight Rating
Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts?
Insiders Of AbCellera Biologics Are Up 20% On Their US$740.0k Purchase
Is AbCellera Biologics (NASDAQ:ABCL) In A Good Position To Invest In Growth?
Watching AbCellera Biologics; Shares See Volume To The Upside, Traders Circulate Ray Blancos Catalyst Trader Action Alert To Buy The Stock Up To $4
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Individual Investors Who Own 34% Along With Institutions Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) Saw Increase in Their Holdings Value Last Week
AbCellera to Present at Upcoming Investor Conferences in December and January
Weekend Reading | The men behind Trump, Pence, and Musk, once again betting on the success of 'venture capital'.
If everyone's thoughts are the same, then no one is thinking.
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
Bloom Burton Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $9
A Quick Look at Today's Ratings for AbCellera Biologics(ABCL.US), With a Forecast Between $7 to $12
Positive Long-Term Outlook for AbCellera Biologics Amidst Short-Term Challenges
AbCellera Biologics: Promising Investment With Robust Antibody Platform and Strategic Growth Plans
Q3 2024 Abcellera Biologics Inc Earnings Call
AbCellera Biologics Analyst Ratings
Benchmark Co. Maintains AbCellera Biologics(ABCL.US) With Hold Rating